Pulmonary Drugs Market Scope and Size by 2031
Pulmonary drugs are used to treat a variety of conditions that affect the lungs. The pulmonary drugs category includes medications for a wide range of diseases, from the common cold to long-term chronic disorders like COPD and asthma. The pulmonary drugs are available in various dosage forms that include, oral tablets, inhalers , liquids, injections and others. The key driving factors for the pulmonary drugs market are, increasing prevalence of pulmonary and respiratory diseases like, COPD, asthma, cystic fibrosis along with new product launches and drug approvals.
MARKET SCOPE
The "Global Pulmonary Drugs Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the pulmonary drugs market with detailed market segmentation by drug class, application and distribution channel. The report provides key statistics on the market status of the leading pulmonary drugs market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
- Based on drug class the market is segmented as, inhaled corticosteroids, long acting beta-2 agonists, antihistamines, vasodilators, short acting beta-2 agonists, and others.
- Based on application the market is segmented as, asthma & COPD, allergic rhinitis, pulmonary arterial hypertension, cystic fibrosis, and others.
- Based on distribution channel the market is segmented as, hospital pharmacies, retail pharmacies, and online pharmacies.
MARKET DYNAMICS
Drivers:
- Increasing prevalence of pulmonary and respiratory diseases like, COPD, asthma, cystic fibrosis along with new product launches and drug approvals.
- Risk factors such as, smoking, unhealthy lifestyles, genetic factors.
- Growing R&D investments to develop more prominent therapies for management of pulmonary disorders.
Restraints:
- However, side effects associated with the prolonged use of pulmonary drugs is expected to restrain market growth during the forecast period.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The pulmonary drugs market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the pulmonary drugs market in these regions.
IMPACT OF COVID-19 ON PULMONARY DRUGS MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities. Majority of pharmaceutical and biopharmaceutical companies are engaged in development of prominent therapies for COVID-19 and this significantly affecting market for pulmonary drugs. But in some instances, few pulmonary drugs are helpful in management of COVID- 19 infection as it affects the lungs. So some pulmonary agents are used to manage the symptoms.
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The pulmonary drugs market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the pulmonary drugs market in these regions.
IMPACT OF COVID-19 ON PULMONARY DRUGS MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities. Majority of pharmaceutical and biopharmaceutical companies are engaged in development of prominent therapies for COVID-19 and this significantly affecting market for pulmonary drugs. But in some instances, few pulmonary drugs are helpful in management of COVID- 19 infection as it affects the lungs. So some pulmonary agents are used to manage the symptoms.
MARKET PLAYERS
The report covers key developments in the pulmonary drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from pulmonary drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for pulmonary drugs in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the pulmonary drugs market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
- Sanofi
- Viatris Inc
- Circassia
- AstraZeneca
- GlaxoSmithKline Plc
- Mallinckrodt
- CHIESI Farmaceutici S.p.A
- Zambon
- Novartis AG
- Merck Sharp and Dohme Corp
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Pulmonary Drugs Market - By Drug Class
1.3.2 Pulmonary Drugs Market - By Application
1.3.3 Pulmonary Drugs Market - By Distribution Channel
1.3.4 Pulmonary Drugs Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. PULMONARY DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1 Bargaining Power of Buyers
4.2.1 Bargaining Power of Suppliers
4.2.1 Threat of Substitute
4.2.1 Threat of New Entrants
4.2.1 Competitive Rivalry
4.3. EXPERT OPINIONS
5. PULMONARY DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. PULMONARY DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. PULMONARY DRUGS - GLOBAL MARKET OVERVIEW
6.2. PULMONARY DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. PULMONARY DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. INHALED CORTICOSTEROIDS
7.3.1. Overview
7.3.2. Inhaled Corticosteroids Market Forecast and Analysis
7.4. LONG ACTING BETA-2 AGONISTS
7.4.1. Overview
7.4.2. Long Acting Beta-2 Agonists Market Forecast and Analysis
7.5. ANTIHISTAMINES
7.5.1. Overview
7.5.2. Antihistamines Market Forecast and Analysis
7.6. VASODILATORS
7.6.1. Overview
7.6.2. Vasodilators Market Forecast and Analysis
7.7. SHORT ACTING BETA-2 AGONISTS
7.7.1. Overview
7.7.2. Short Acting Beta-2 Agonists Market Forecast and Analysis
7.8. OTHERS
7.8.1. Overview
7.8.2. Others Market Forecast and Analysis
8. PULMONARY DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. ASTHMA AND COPD
8.3.1. Overview
8.3.2. Asthma and COPD Market Forecast and Analysis
8.4. ALLERGIC RHINITIS
8.4.1. Overview
8.4.2. Allergic Rhinitis Market Forecast and Analysis
8.5. PULMONARY ARTERIAL HYPERTENSION
8.5.1. Overview
8.5.2. Pulmonary Arterial Hypertension Market Forecast and Analysis
8.6. CYSTIC FIBROSIS
8.6.1. Overview
8.6.2. Cystic Fibrosis Market Forecast and Analysis
8.7. OTHERS
8.7.1. Overview
8.7.2. Others Market Forecast and Analysis
9. PULMONARY DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACIES
9.3.1. Overview
9.3.2. Hospital Pharmacies Market Forecast and Analysis
9.4. RETAIL PHARMACIES
9.4.1. Overview
9.4.2. Retail Pharmacies Market Forecast and Analysis
9.5. ONLINE PHARMACIES
9.5.1. Overview
9.5.2. Online Pharmacies Market Forecast and Analysis
10. PULMONARY DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Pulmonary Drugs Market Overview
10.1.2 North America Pulmonary Drugs Market Forecasts and Analysis
10.1.3 North America Pulmonary Drugs Market Forecasts and Analysis - By Drug Class
10.1.4 North America Pulmonary Drugs Market Forecasts and Analysis - By Application
10.1.5 North America Pulmonary Drugs Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Pulmonary Drugs Market Forecasts and Analysis - By Countries
10.1.6.1 United States Pulmonary Drugs Market
10.1.6.1.1 United States Pulmonary Drugs Market by Drug Class
10.1.6.1.2 United States Pulmonary Drugs Market by Application
10.1.6.1.3 United States Pulmonary Drugs Market by Distribution Channel
10.1.6.2 Canada Pulmonary Drugs Market
10.1.6.2.1 Canada Pulmonary Drugs Market by Drug Class
10.1.6.2.2 Canada Pulmonary Drugs Market by Application
10.1.6.2.3 Canada Pulmonary Drugs Market by Distribution Channel
10.1.6.3 Mexico Pulmonary Drugs Market
10.1.6.3.1 Mexico Pulmonary Drugs Market by Drug Class
10.1.6.3.2 Mexico Pulmonary Drugs Market by Application
10.1.6.3.3 Mexico Pulmonary Drugs Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Pulmonary Drugs Market Overview
10.2.2 Europe Pulmonary Drugs Market Forecasts and Analysis
10.2.3 Europe Pulmonary Drugs Market Forecasts and Analysis - By Drug Class
10.2.4 Europe Pulmonary Drugs Market Forecasts and Analysis - By Application
10.2.5 Europe Pulmonary Drugs Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Pulmonary Drugs Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Pulmonary Drugs Market
10.2.6.1.1 Germany Pulmonary Drugs Market by Drug Class
10.2.6.1.2 Germany Pulmonary Drugs Market by Application
10.2.6.1.3 Germany Pulmonary Drugs Market by Distribution Channel
10.2.6.2 France Pulmonary Drugs Market
10.2.6.2.1 France Pulmonary Drugs Market by Drug Class
10.2.6.2.2 France Pulmonary Drugs Market by Application
10.2.6.2.3 France Pulmonary Drugs Market by Distribution Channel
10.2.6.3 Italy Pulmonary Drugs Market
10.2.6.3.1 Italy Pulmonary Drugs Market by Drug Class
10.2.6.3.2 Italy Pulmonary Drugs Market by Application
10.2.6.3.3 Italy Pulmonary Drugs Market by Distribution Channel
10.2.6.4 Spain Pulmonary Drugs Market
10.2.6.4.1 Spain Pulmonary Drugs Market by Drug Class
10.2.6.4.2 Spain Pulmonary Drugs Market by Application
10.2.6.4.3 Spain Pulmonary Drugs Market by Distribution Channel
10.2.6.5 United Kingdom Pulmonary Drugs Market
10.2.6.5.1 United Kingdom Pulmonary Drugs Market by Drug Class
10.2.6.5.2 United Kingdom Pulmonary Drugs Market by Application
10.2.6.5.3 United Kingdom Pulmonary Drugs Market by Distribution Channel
10.2.6.6 Rest of Europe Pulmonary Drugs Market
10.2.6.6.1 Rest of Europe Pulmonary Drugs Market by Drug Class
10.2.6.6.2 Rest of Europe Pulmonary Drugs Market by Application
10.2.6.6.3 Rest of Europe Pulmonary Drugs Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Pulmonary Drugs Market Overview
10.3.2 Asia-Pacific Pulmonary Drugs Market Forecasts and Analysis
10.3.3 Asia-Pacific Pulmonary Drugs Market Forecasts and Analysis - By Drug Class
10.3.4 Asia-Pacific Pulmonary Drugs Market Forecasts and Analysis - By Application
10.3.5 Asia-Pacific Pulmonary Drugs Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Pulmonary Drugs Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Pulmonary Drugs Market
10.3.6.1.1 Australia Pulmonary Drugs Market by Drug Class
10.3.6.1.2 Australia Pulmonary Drugs Market by Application
10.3.6.1.3 Australia Pulmonary Drugs Market by Distribution Channel
10.3.6.2 China Pulmonary Drugs Market
10.3.6.2.1 China Pulmonary Drugs Market by Drug Class
10.3.6.2.2 China Pulmonary Drugs Market by Application
10.3.6.2.3 China Pulmonary Drugs Market by Distribution Channel
10.3.6.3 India Pulmonary Drugs Market
10.3.6.3.1 India Pulmonary Drugs Market by Drug Class
10.3.6.3.2 India Pulmonary Drugs Market by Application
10.3.6.3.3 India Pulmonary Drugs Market by Distribution Channel
10.3.6.4 Japan Pulmonary Drugs Market
10.3.6.4.1 Japan Pulmonary Drugs Market by Drug Class
10.3.6.4.2 Japan Pulmonary Drugs Market by Application
10.3.6.4.3 Japan Pulmonary Drugs Market by Distribution Channel
10.3.6.5 South Korea Pulmonary Drugs Market
10.3.6.5.1 South Korea Pulmonary Drugs Market by Drug Class
10.3.6.5.2 South Korea Pulmonary Drugs Market by Application
10.3.6.5.3 South Korea Pulmonary Drugs Market by Distribution Channel
10.3.6.6 Rest of Asia-Pacific Pulmonary Drugs Market
10.3.6.6.1 Rest of Asia-Pacific Pulmonary Drugs Market by Drug Class
10.3.6.6.2 Rest of Asia-Pacific Pulmonary Drugs Market by Application
10.3.6.6.3 Rest of Asia-Pacific Pulmonary Drugs Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Pulmonary Drugs Market Overview
10.4.2 Middle East and Africa Pulmonary Drugs Market Forecasts and Analysis
10.4.3 Middle East and Africa Pulmonary Drugs Market Forecasts and Analysis - By Drug Class
10.4.4 Middle East and Africa Pulmonary Drugs Market Forecasts and Analysis - By Application
10.4.5 Middle East and Africa Pulmonary Drugs Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Pulmonary Drugs Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Pulmonary Drugs Market
10.4.6.1.1 South Africa Pulmonary Drugs Market by Drug Class
10.4.6.1.2 South Africa Pulmonary Drugs Market by Application
10.4.6.1.3 South Africa Pulmonary Drugs Market by Distribution Channel
10.4.6.2 Saudi Arabia Pulmonary Drugs Market
10.4.6.2.1 Saudi Arabia Pulmonary Drugs Market by Drug Class
10.4.6.2.2 Saudi Arabia Pulmonary Drugs Market by Application
10.4.6.2.3 Saudi Arabia Pulmonary Drugs Market by Distribution Channel
10.4.6.3 U.A.E Pulmonary Drugs Market
10.4.6.3.1 U.A.E Pulmonary Drugs Market by Drug Class
10.4.6.3.2 U.A.E Pulmonary Drugs Market by Application
10.4.6.3.3 U.A.E Pulmonary Drugs Market by Distribution Channel
10.4.6.4 Rest of Middle East and Africa Pulmonary Drugs Market
10.4.6.4.1 Rest of Middle East and Africa Pulmonary Drugs Market by Drug Class
10.4.6.4.2 Rest of Middle East and Africa Pulmonary Drugs Market by Application
10.4.6.4.3 Rest of Middle East and Africa Pulmonary Drugs Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Pulmonary Drugs Market Overview
10.5.2 South and Central America Pulmonary Drugs Market Forecasts and Analysis
10.5.3 South and Central America Pulmonary Drugs Market Forecasts and Analysis - By Drug Class
10.5.4 South and Central America Pulmonary Drugs Market Forecasts and Analysis - By Application
10.5.5 South and Central America Pulmonary Drugs Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Pulmonary Drugs Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Pulmonary Drugs Market
10.5.6.1.1 Brazil Pulmonary Drugs Market by Drug Class
10.5.6.1.2 Brazil Pulmonary Drugs Market by Application
10.5.6.1.3 Brazil Pulmonary Drugs Market by Distribution Channel
10.5.6.2 Argentina Pulmonary Drugs Market
10.5.6.2.1 Argentina Pulmonary Drugs Market by Drug Class
10.5.6.2.2 Argentina Pulmonary Drugs Market by Application
10.5.6.2.3 Argentina Pulmonary Drugs Market by Distribution Channel
10.5.6.3 Rest of South and Central America Pulmonary Drugs Market
10.5.6.3.1 Rest of South and Central America Pulmonary Drugs Market by Drug Class
10.5.6.3.2 Rest of South and Central America Pulmonary Drugs Market by Application
10.5.6.3.3 Rest of South and Central America Pulmonary Drugs Market by Distribution Channel
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. PULMONARY DRUGS MARKET, KEY COMPANY PROFILES
12.1. SANOFI
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. VIATRIS INC
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. CIRCASSIA
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. ASTRAZENECA
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. GLAXOSMITHKLINE PLC
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. MALLINCKRODT
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. CHIESI FARMACEUTICI S.P.A
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. ZAMBON
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. NOVARTIS AG
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. MERCK SHARP AND DOHME CORP
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
- Sanofi
- Viatris Inc
- Circassia
- AstraZeneca
- GlaxoSmithKline Plc
- Mallinckrodt
- CHIESI Farmaceutici S.p.A
- Zambon
- Novartis AG
- Merck Sharp and Dohme Corp
- Teva Pharmaceutical Industries Ltd
- Cipla Inc.
- Sun Pharmaceutical Industries Ltd.
- F. Hoffmann-La Roche Ltd
- Glenmark Pharmaceutical Inc., USA
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For